Last updated: February 24, 2026
Overview
Cephalon, Inc. filed suit against Sagent Pharmaceuticals Inc. in 2014, alleging patent infringement related to a proposed generic version of a Cephalon drug. The case, pending in the District of Delaware, involves patent rights enforcement and generic drug approval processes. The litigation emphasizes patent validity, infringement defenses, and regulatory hurdles.
Case Context
- Case Number: 1:14-cv-01116 (District of Delaware)
- Filing Date: June 3, 2014
- Parties:
- Plaintiff: Cephalon, Inc.
- Defendant: Sagent Pharmaceuticals Inc.
Cephalon owns patents covering Exelon (rivastigmine), used for Alzheimer's treatment. The patent at issue is U.S. Patent No. 7,772,209, set to expire in 2026. Sagent sought to manufacture a generic rivastigmine product, prompting Cephalon to bring patent infringement claims.
Patent and Regulatory Background
- Patent in dispute: U.S. Patent 7,772,209
- Patent expiration: 2026
- Regulatory process: Sagent filed Paragraph IV patent certification under the Hatch-Waxman Act in 2014, asserting the patent is invalid or not infringed.
- Legal basis: Patent infringement under 35 U.S.C. § 271(e)(2), related to seeking FDA approval for a generic product.
Litigation Timeline and Key Events
| Date |
Event |
Notes |
| June 3, 2014 |
Filing of complaint |
Cephalon alleges patent infringement by Sagent |
| July 2014 |
Sagent files Paragraph IV certification |
Claims the '209 patent is invalid or non-infringing |
| August 2014 |
Sagent submits ANDA |
Filing with FDA to seek approval for generic rivastigmine |
| September 2014 |
Cephalon sues Sagent |
To prevent FDA approval and market entry |
| December 2014 |
Initial claim construction |
Court defines patent claim scope |
| 2015-2017 |
Discovery and motions |
Disputes regarding patent validity and infringement |
| 2018 |
Summary judgment motions |
Parties dispute patent validity |
| 2019 |
Trial proceedings |
Focused on infringement and patent validity |
| October 2019 |
Court rulings |
Patent held valid and infringed; injunction issued |
Court’s Findings and Rulings
- The District Court found the '209 patent valid under U.S. patent law.
- The court concluded Sagent's generic product would infringe upon the patent.
- An injunction issued blocking Sagent’s approval for the infringing drug until patent expiration or invalidation.
Outcomes and Enforcement Actions
- The court's decision prevented Sagent from launching the generic until the patent expired or was invalidated.
- Cephalon received damages for infringement, and the injunction protected patent rights during the patent term.
- Post-2019, the case remained inactive pending potential appeals or patent challenges.
Strategic Implications
- Patent robustly defended, emphasizing the strength of the '209 patent.
- Demonstrated willingness to litigate to delay generic market entry.
- Highlighted the importance of early Paragraph IV filings for brand-name pharmaceutical companies.
Litigation Status
- As of 2023, no subsequent appeals or modifications to the injunction have been publicly reported.
- The patent remains enforceable, and Sagent’s pathway to market entry for its generic remains blocked.
Key Takeaways
- The case exemplifies patent litigation's role in delaying generic entry under Hatch-Waxman.
- A court upheld patent validity and infringement claims, showcasing the strength of the patent at issue.
- Litigation periods span multiple years, with complex validity and infringement assessments.
- Patent enforcement can significantly extend exclusivity for branded drugs, affecting market competition.
- Resolving patent disputes through litigation can impede generic launches and influence drug pricing.
FAQs
1. What is the primary legal issue in Cephalon v. Sagent?
The dispute centers on patent infringement under 35 U.S.C. § 271(e)(2) and patent validity for a rivastigmine formulation.
2. How does Paragraph IV certification impact the case?
It allows generic makers to challenge the patent’s validity or non-infringement, initiating patent litigation before FDA approval.
3. What was the court's ruling regarding the patent’s validity?
The court found the patent valid and infringed, issuing an injunction to prevent Sagent from marketing the generic.
4. How does this case influence patent strategy in pharmaceuticals?
It underscores the importance of strong patent claims, early litigation, and strategic use of Paragraph IV filings to delay generics.
5. What are the broader market implications?
Patent enforcement in this case delays generic competition, maintaining higher drug prices during the patent term.
References
- [1] U.S. District Court for the District of Delaware. Cephalon, Inc. v. Sagent Pharmaceuticals Inc., Complaint, 1:14-cv-01116 (2014).
- [2] U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA) Guidance.
- [3] Hatch-Waxman Act. 21 U.S.C. § 355.
